LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Strontium ranelate as a possible disease-modifying osteoarthritis drug: a systematic review.

    Rodrigues, T A / Freire, A O / Bonfim, B F / Cartágenes, M S S / Garcia, J B S

    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas

    2018  Volume 51, Issue 8, Page(s) e7440

    Abstract: ... findings are rare. Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis ... in the progression of the disease. The so-called disease-modifying OA drugs have been frequently investigated but conclusive ... Considering that osteoarthritis (OA) is the most prevalent joint disease worldwide, multiple ...

    Abstract Considering that osteoarthritis (OA) is the most prevalent joint disease worldwide, multiple pharmacological treatments have been proposed to alter the articular structure with potential benefit in the progression of the disease. The so-called disease-modifying OA drugs have been frequently investigated but conclusive findings are rare. Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects in decreasing the risk of fractures and possible effect in reducing the progression of OA. The objective of this review was to demonstrate the current panorama of knowledge on the use of SrRan in clinical and experimental models, clarifying its mechanisms of action and describing possible anti-nociceptive and anti-inflammatory effects. The systematic review was based on the PRISMA statement and included articles that are indexed in scientific databases. Fifteen studies were included: seven pre-clinical and eight clinical studies. Despite the limited number of studies, the results suggest a positive effect of SrRan in patients with OA, through changes in functional capacity and reduction of progression of morphological parameters and joint degradation, with moderate quality of evidence for those clinical outcomes. Novel studies are necessary to elucidate the molecular targets of SrRan, focusing on anti-inflammatory effects and histological changes promoted by SrRan, which seemed to reduce the progression of OA in the experimental and clinical studies.
    MeSH term(s) Animals ; Arthralgia/drug therapy ; Bone Density Conservation Agents/pharmacology ; Bone Density Conservation Agents/therapeutic use ; Bone Remodeling/drug effects ; Bone Resorption/drug therapy ; Cartilage, Articular/drug effects ; Disease Progression ; Humans ; Osteoarthritis/drug therapy ; Thiophenes/pharmacology ; Thiophenes/therapeutic use
    Chemical Substances Bone Density Conservation Agents ; Thiophenes ; strontium ranelate (04NQ160FRU)
    Language English
    Publishing date 2018-06-18
    Publishing country Brazil
    Document type Journal Article ; Review ; Systematic Review
    ZDB-ID 786234-9
    ISSN 1414-431X ; 0100-879X
    ISSN (online) 1414-431X
    ISSN 0100-879X
    DOI 10.1590/1414-431x20187440
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Strontium ranelate as a possible disease-modifying osteoarthritis drug

    T.A. Rodrigues / A.O. Freire / B.F. Bonfim / M.S.S. Cartágenes / J.B.S. Garcia

    Brazilian Journal of Medical and Biological Research, Vol 51, Iss

    a systematic review

    2018  Volume 8

    Abstract: ... findings are rare. Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis ... in the progression of the disease. The so-called disease-modifying OA drugs have been frequently investigated but conclusive ... Considering that osteoarthritis (OA) is the most prevalent joint disease worldwide, multiple ...

    Abstract Considering that osteoarthritis (OA) is the most prevalent joint disease worldwide, multiple pharmacological treatments have been proposed to alter the articular structure with potential benefit in the progression of the disease. The so-called disease-modifying OA drugs have been frequently investigated but conclusive findings are rare. Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects in decreasing the risk of fractures and possible effect in reducing the progression of OA. The objective of this review was to demonstrate the current panorama of knowledge on the use of SrRan in clinical and experimental models, clarifying its mechanisms of action and describing possible anti-nociceptive and anti-inflammatory effects. The systematic review was based on the PRISMA statement and included articles that are indexed in scientific databases. Fifteen studies were included: seven pre-clinical and eight clinical studies. Despite the limited number of studies, the results suggest a positive effect of SrRan in patients with OA, through changes in functional capacity and reduction of progression of morphological parameters and joint degradation, with moderate quality of evidence for those clinical outcomes. Novel studies are necessary to elucidate the molecular targets of SrRan, focusing on anti-inflammatory effects and histological changes promoted by SrRan, which seemed to reduce the progression of OA in the experimental and clinical studies.
    Keywords Osteoarthritis ; Strontium ranelate ; Treatment ; Pain ; Symptoms ; Medicine (General) ; R5-920 ; Biology (General) ; QH301-705.5
    Subject code 610
    Language English
    Publishing date 2018-06-01T00:00:00Z
    Publisher Associação Brasileira de Divulgação Científica
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top